Review





Similar Products

tissue microarray metastatic melanoma (bcc38218  (U.S Biomax Inc)
90
U.S Biomax Inc tissue microarray metastatic melanoma (bcc38218
a DLC1 copy-number variation analysis of liver cancer ( n = 372) and melanoma ( n = 363) cases from the TCGA database. Each dot represents data from one patient. b RNA-sequencing analysis of DLC1 mRNA levels in liver cancer ( n = 369) and melanoma ( n = 461) samples compared with normal liver ( n = 160) and skin ( n = 558) tissues, respectively, from the TCGA database. * p < 0.05, by Student’s t test. c , d Immunofluorescence of DLC1 and MELAN A in 45 primary melanoma specimens in a tissue <t>microarray</t> (TMA). White arrowheads indicate melanoma cells with overlapping expression of nuclear DLC1 and cytoplasmic MELAN A. e Percentage of cases with DLC1 + /MELAN A + , DLC1 + /MELAN A − , DLC1 − /MELAN A + , and DLC1 − /MELAN A − expression . Chi-squared test, p = 0.033. f Percentage of cases with nuclear DLC1 (strong) + cytoplasmic and nuclear DLC1 (weak) + cytoplasmic in the total cohort and MELAN A + cohort. g Western blot detection of DLC1, FOXK1. and MMP9 expression levels in normal melanocytes (HEMa-LP) and a panel of melanoma cell lines. GAPDH served as a loading control. The signal intensities of protein bands are shown in arbitrary units after normalization with GAPDH. Scale bar: 100 µM.
Tissue Microarray Metastatic Melanoma (Bcc38218, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tissue+microarray+metastatic+melanoma+(bcc38218/tissue+microarray+metastatic+melanoma++bcc38218/pmc07220869-225-0-13
Average 90 stars, based on 1 article reviews
tissue microarray metastatic melanoma (bcc38218 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


a DLC1 copy-number variation analysis of liver cancer ( n = 372) and melanoma ( n = 363) cases from the TCGA database. Each dot represents data from one patient. b RNA-sequencing analysis of DLC1 mRNA levels in liver cancer ( n = 369) and melanoma ( n = 461) samples compared with normal liver ( n = 160) and skin ( n = 558) tissues, respectively, from the TCGA database. * p < 0.05, by Student’s t test. c , d Immunofluorescence of DLC1 and MELAN A in 45 primary melanoma specimens in a tissue microarray (TMA). White arrowheads indicate melanoma cells with overlapping expression of nuclear DLC1 and cytoplasmic MELAN A. e Percentage of cases with DLC1 + /MELAN A + , DLC1 + /MELAN A − , DLC1 − /MELAN A + , and DLC1 − /MELAN A − expression . Chi-squared test, p = 0.033. f Percentage of cases with nuclear DLC1 (strong) + cytoplasmic and nuclear DLC1 (weak) + cytoplasmic in the total cohort and MELAN A + cohort. g Western blot detection of DLC1, FOXK1. and MMP9 expression levels in normal melanocytes (HEMa-LP) and a panel of melanoma cell lines. GAPDH served as a loading control. The signal intensities of protein bands are shown in arbitrary units after normalization with GAPDH. Scale bar: 100 µM.

Journal: Oncogene

Article Title: Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma

doi: 10.1038/s41388-020-1274-8

Figure Lengend Snippet: a DLC1 copy-number variation analysis of liver cancer ( n = 372) and melanoma ( n = 363) cases from the TCGA database. Each dot represents data from one patient. b RNA-sequencing analysis of DLC1 mRNA levels in liver cancer ( n = 369) and melanoma ( n = 461) samples compared with normal liver ( n = 160) and skin ( n = 558) tissues, respectively, from the TCGA database. * p < 0.05, by Student’s t test. c , d Immunofluorescence of DLC1 and MELAN A in 45 primary melanoma specimens in a tissue microarray (TMA). White arrowheads indicate melanoma cells with overlapping expression of nuclear DLC1 and cytoplasmic MELAN A. e Percentage of cases with DLC1 + /MELAN A + , DLC1 + /MELAN A − , DLC1 − /MELAN A + , and DLC1 − /MELAN A − expression . Chi-squared test, p = 0.033. f Percentage of cases with nuclear DLC1 (strong) + cytoplasmic and nuclear DLC1 (weak) + cytoplasmic in the total cohort and MELAN A + cohort. g Western blot detection of DLC1, FOXK1. and MMP9 expression levels in normal melanocytes (HEMa-LP) and a panel of melanoma cell lines. GAPDH served as a loading control. The signal intensities of protein bands are shown in arbitrary units after normalization with GAPDH. Scale bar: 100 µM.

Article Snippet: Tissue microarray of malignant melanoma (ME1002b) and metastatic melanoma (BCC38218) were purchased from US Biomax Inc.

Techniques: RNA Sequencing Assay, Immunofluorescence, Microarray, Expressing, Western Blot